MedTrace Logo

Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance

NCT05703009 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-02-06

No results posted yet for this study

Summary

SSDXA-14 is a Phase 2 (feasibility/pilot) double-blind, placebo-controlled, crossover study to evaluate the efficacy and safety of sacrosidase and placebo in 25 subjects objectively diagnosed with fructan intolerance.

Conditions

  • Fructan Intolerance

Interventions

DRUG

Sacrosidase Oral Solution

Study drug

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • QOL Medical, LLC

    lead INDUSTRY

Principal Investigators

  • Weng Tao, M.D., Ph. D · QOL Medical, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-05
Primary Completion
2024-01-22
Completion
2024-01-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05703009 on ClinicalTrials.gov